Crinetics presents efficacy, safety, outcome of ENDO 2023

Crinetics Pharmaceuticals presented efficacy, safety and patient-reported outcome data at ENDO 2023 for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 agonist in Phase 3 clinical development for the treatment of acromegaly. The Endocrine Society’s annual meeting, ENDO 2023, was held June 15-18, 2023, in Chicago, Illinois. Results demonstrated that patients switching from therapy with injected somatostatin receptor ligands to oral paltusotine maintained stable levels of key measures associated with acromegaly including insulin-like growth factor 1, growth hormone, acromegaly symptom diary score, blood pressure, hemoglobin A1c, ring size, and body weight.